Savara Securities Suit Deadline Nears as Investor Firms Urge Action
The case stems from the FDA's refusal to file the MOLBREEVI application over missing CMC data.
Overview
- Faruqi & Faruqi, Kirby McInerney, and Rosen Law Firm issued fresh notices urging Savara investors to seek lead-plaintiff appointment by November 7, 2025.
- Attorneys say a federal securities class action has been filed covering purchases from March 7, 2024 through May 23, 2025.
- Savara disclosed on May 27, 2025 that the FDA refused to file its MOLBREEVI Biologics License Application, citing an incomplete submission and requests for additional CMC data.
- Savara shares fell $0.90, or 31.69%, to close at $1.94 on May 27, 2025 following the disclosure.
- The complaint alleges misleading statements about the BLA’s completeness, timing, and capital needs, and notices emphasize that no class has been certified and no lead plaintiff has been appointed.